Search

Your search keyword '"Weill, Alain"' showing total 1,053 results
Start Over Author "Weill, Alain"
1,053 results on '"Weill, Alain"'

7. Nonaneurysmal perimesencephalic subarachnoid hemorrhage on noncontrast head CT: An accuracy, inter-rater, and intra-rater reliability study

Author

Benomar, Anass, Diestro, Jose Danilo B., Darabid, Houssam, Saydy, Karim, Tzaneva, Lora, Li, Jimmy, Zarour, Eleyine, Tanguay, William, El Sayed, Nohad, Padilha, Igor Gomes, Létourneau-Guillon, Laurent, Bard, Céline, Nelson, Kristoff, Weill, Alain, Roy, Daniel, Eneling, Johanna, Boisseau, William, Nguyen, Thanh N., Abdalkader, Mohamad, Najjar, Ahmed A., Nehme, Ahmad, Lemoine, Émile, Jacquin, Gregory, Bergeron, David, Brunette-Clément, Tristan, Chaalala, Chiraz, Bojanowski, Michel W., Labidi, Moujahed, Jabre, Roland, Ignacio, Katrina H.D., Omar, Abdelsimar T., II, Volders, David, Dmytriw, Adam A., Hak, Jean-François, Forestier, Géraud, Holay, Quentin, Olatunji, Richard, Alhabli, Ibrahim, Nico, Lorena, Shankar, Jai J.S., Guenego, Adrien, Pascual, Jose L.R., Marotta, Thomas R., Errázuriz, Juan I., Lin, Amy W., Alves, Aderaldo Costa, Jr, Fahed, Robert, Hawkes, Christine, Lee, Hubert, Magro, Elsa, Sheikhi, Lila, Darsaut, Tim E., and Raymond, Jean

Published
2024
Full Text
View/download PDF

17. Non-contrast CT markers of intracerebral hematoma expansion: a reliability study

Author

Nehme, Ahmad, Ducroux, Célina, Panzini, Marie-Andrée, Bard, Céline, Bereznyakova, Olena, Boisseau, William, Deschaintre, Yan, Diestro, Jose Danilo Bengzon, Guilbert, François, Jacquin, Grégory, Maallah, Mohamed Taoubane, Nelson, Kristoff, Padilha, Igor Gomes, Poppe, Alexandre Y., Rioux, Bastien, Roy, Daniel, Touma, Lahoud, Weill, Alain, Gioia, Laura C., and Létourneau-Guillon, Laurent

Published
2022
Full Text
View/download PDF

18. Patient Selection in a Pragmatic Study on the Management of Patients with Brain Arteriovenous Malformations

Author

Raymond, Jean, Roy, Daniel, Weill, Alain, Iancu, Daniela, Bojanowski, Michel W., Chaalala, Chiraz, Darsaut, Tim E., O'Kelly, Cian J., Chow, Michael MC., Findlay, J. Max, Rempel, Jeremy L., Fahed, Robert, Lesiuk, Howard, Drake, Brian, Santos, Marlene dos, Gentric, Jean-Christophe, Nonent, Michel, Ognard, Julien, El-Aouni, Mourad Cheddad, Magro, Elsa, Seizeur, Romuald, Timsit, Serge, Pradier, Olivier, Desal, Hubert, Boursier, Romain, Thillays, François, Roualdes, Vincent, Piotin, Michel, Blanc, Raphael, Aldea, Sorin, Cognard, Christophe, Januel, Anne-Christine, Sabatier, Jean-François, Calviere, Lionel, Gauvrit, Jean Yves, Raoult, Hélène, Eugene, François, Le Bras, Anthony, Ferre, Jean-Christophe, Paya, Christophe, Morandi, Xavier, Lecouillard, Isabelle, Nouhaud, Elodie, Ronziere, Thomas, Trystram, Denis, Naggara, Olivier, Rodriguez-Regent, Christine, Kerleroux, Basile, Barbier, Charlotte, Gaberel, Thomas, Emery, Evelyne, Touze, Emmanuel, Papagiannaki, Chrysanthi, Derrey, Stéphane, Eker, Omer, Riva, Roberto, Pellisou-Guyotat, Isabelle, Guyotat, Jacques, Berhouma, Monsef, Dumot, Chloé, Biondi, Alessandra, Thines, Laurent, Bougaci, Nassim, Charbonnier, Guillaume, Bracard, Serge, Anxionnat, René, Gory, Benjamin, Civit, Thierry, Bernier-Chastagner, Valérie, Barreau, Xavier, Marnat, Gaultier, Jecko, Vincent, Penchet, Guillaume, Gimbert, Edouard, Huchet, Aymeri, Herbreteau, Denis, Boulouis, Grégoire, Bibi, Richard, Ifergan, Héloïse, Janot, Kévin, Velut, Stéphane, Brunel, Hervé, Roche, Pierre-Hugues, Graillon, Thomas, Peyriere, Hadrien, Kaya, Jean-Marc, Touta, Adamou, Troude, Lucas, Boissonneau, Sébastien, Clarençon, Frédéric, Shotar, Eimad, Sourour, Nader, Lenck, Stéphanie, Premat, Kévin, Boch, Anne-Laure, Cornu, Philippe, Nouet, Aurélien, Costalat, Vincent, Bonafe, Alain, Dargazanli, Cyril, Gascou, Gregory, Lefevre, Pierre-Henri, Riquelme, Carlos, Le Corre, Marine, Beaujeux, Rémy, Pop, Raoul, Proust, François, Cebula, Hélène, Ollivier, Irène, Spatola, Giorgio, Spell, Laurent, Chalumeau, Vanessa, Gallas, Sophie, Ikka, Léon, Mihalea, Cristian, Ozanne, Augustin, Caroff, Jildaz, Chabert, Emmanuel, Mounayer, Charbel, Rouchaud, Aymeric, Caire, François, Ricolfi, Frédéric, Thouant, Pierre, Cao, Catherine, Mourier, Klaus-Luc, Farah, Walid, Nguyen, Thanh N., Abdalkader, Mohamad, Huynh, Thien, Tawk, Rabih G., Carlson, Andrew P., Oliveira Silva, Luciana Alves, de Lima Froio, Nayara, Silva, Gisele Sampaio, Mont’Alverne, Francisco J.A., Martins, Jose Luri, Mendes, George Nunes, Miranda, Rodrigo Rivera, Benomar, Anass, Nico, Lorena, Bacchus, Emma, Klink, Ruby, Pelissou-Guyotat, Isabelle, Gauvrit, Jean-Yves, Bourcier, Romain, Viard, Geraldine, and Gevry, Guylaine

Published
2023
Full Text
View/download PDF

22. Middle Cerebral Artery Aneurysm Trial (MCAAT): A Randomized Care Trial Comparing Surgical and Endovascular Management of MCA Aneurysm Patients

Author

Darsaut, Tim E., Keough, Michael B., Boisseau, William, Findlay, J. Max, Bojanowski, Michel W., Chaalala, Chiraz, Iancu, Daniela, Weill, Alain, Roy, Daniel, Estrade, Laurent, Lejeune, Jean-Paul, Januel, Anne-Christine, Carlson, Andrew P., Sauvageau, Eric, Al-Jehani, Hosam, Orlov, Kirill, Aldea, Sorin, Piotin, Michel, Gaberel, Thomas, Gevry, Guylaine, and Raymond, Jean

Published
2022
Full Text
View/download PDF

24. Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies.

Author

Semenzato, Laura, Le Vu, Stéphane, Botton, Jérémie, Bertrand, Marion, Jabagi, Marie-Joelle, Drouin, Jérôme, Cuenot, François, Zores, Florian, Dray-Spira, Rosemary, Weill, Alain, and Zureik, Mahmoud

Abstract

Key Points: Question: What is the long-term prognosis of myocarditis after COVID-19 mRNA vaccination and do clinical outcomes and medical management differ from myocarditis of other origins? Finding: In this nationwide cohort study including 4635 patients hospitalized for myocarditis in France during the first 1.5 years after COVID-19 vaccination, the 558 individuals with postvaccine myocarditis had less severe cardiovascular events than those with myocarditis of other origins at 18 months of follow-up. However, affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge. Meaning: These elements should be taken into account for ongoing and future mRNA vaccine recommendations. Importance: Although patients with myocarditis after COVID-19 mRNA vaccination appear to have a good prognosis near hospital discharge, their longer-term prognosis and management remain unknown. Objective: To study the cardiovascular complications of post–COVID-19 mRNA vaccination myocarditis and other types of myocarditis during an 18-month follow-up, as well as disease management based on a study of the frequency of medical procedures and drug prescriptions. Design, Setting, and Participants: In this cohort study based on the French National Health Data System, all individuals aged 12 to 49 years hospitalized for myocarditis in France between December 27, 2020, and June 30, 2022, were identified. Exposure: Individuals were categorized as having postvaccine myocarditis (within 7 days after COVID-19 mRNA vaccine), post–COVID-19 myocarditis (within 30 days of SARS-CoV-2 infection), or conventional myocarditis. Main Outcomes and Measures: The occurrence of clinical outcomes (hospital readmission for myopericarditis, other cardiovascular events, all-cause death, and a composite outcome of these events) over the 18 months following hospital admission were analyzed using weighted Cox models to standardize the comparisons with the conventional myocarditis group. Also, medical management after hospital discharge was longitudinally assessed using generalized estimated equation models. Results: In total, 4635 individuals were hospitalized for myocarditis: 558 with postvaccine myocarditis, 298 with post–COVID-19 myocarditis, and 3779 with conventional myocarditis. Patients with postvaccine myocarditis were younger than those with post–COVID-19 and conventional myocarditis (mean [SD] age of 25.9 [8.6], 31.0 [10.9], and 28.3 [9.4] years, respectively) and were more frequently men (84%, 67%, and 79%). Patients with postvaccine myocarditis had a lower standardized incidence of the composite clinical outcome than those with conventional myocarditis (32/558 vs 497/3779 events; weighted hazard ratio, 0.55 [95% CI, 0.36-0.86]), whereas individuals with post–COVID-19 myocarditis had similar results (36/298 events; weighted hazard ratio, 1.04 [95% CI, 0.70-1.52]). The standardized frequency of medical procedures and drugs prescribed in patients with postvaccine myocarditis or post–COVID-19 myocarditis followed a similar trend in the 18 months following hospital discharge to that of patients with conventional myocarditis. Conclusions and Relevance: Patients with post–COVID-19 mRNA vaccination myocarditis, contrary to those with post–COVID-19 myocarditis, show a lower frequency of cardiovascular complications than those with conventional myocarditis at 18 months. However, affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge. This cohort study examines cardiovascular complications of postvaccine and other types of myocarditis (ie, post–COVID-19 and conventional myocarditis) during 18-month follow-up. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study.

Author

Hoisnard, Lea, Meyer, Antoine, Dray‐Spira, Rosemary, Weill, Alain, Zureik, Mahmoud, and Sbidian, Emilie

Subjects
INTESTINAL perforation -- Risk factors, DRUG therapy for rheumatism, RISK assessment, HETEROCYCLIC compounds, ANTI-inflammatory agents, ANTIRHEUMATIC agents, DESCRIPTIVE statistics, JANUS kinases, LONGITUDINAL method, ADALIMUMAB, NEUROTRANSMITTER uptake inhibitors, COMPARATIVE studies, CONFIDENCE intervals, DISEASE incidence
Abstract

Objective: To compare the risk of gastrointestinal perforation (GIP), a rare but serious adverse event, in patients who a JAK inhibitor (JAKi; tofacitinib, baricitinib, upadacitinib, or filgotinib) versus adalimumab (tumor necrosis factor inhibitor) among a comprehensive real‐world population of patients with rheumatic diseases. Methods: We conducted a nationwide population‐based cohort study of the French national health data system, the exposed group that received a JAKi and the comparison group adalimumab. We included all individuals with a rheumatic disease who had their first dispensation of these treatments from July 2017 to December 2021. The primary endpoint was the occurrence of GIP (end of follow‐up May 2022). Weighted hazard ratios (wHRs) were estimated with the inverse probability of treatment weighting method to account for confounding factors. Concomitant administration of systemic glucocorticoids, nonsteroidal anti‐inflammatory drugs, and proton‐pump inhibitors were time‐varying variables. Results: The cohort included 39,758 patients: 12,335 and 27,423 in the groups that received a JAKi and adalimumab (mean age 58.2 and 47.3 years; female 76% and 58%; rheumatoid arthritis 85.3% and 27.3%, and psoriatic arthritis/axial spondyloarthritis 14.7% and 72.7%), respectively. During follow‐up, 38 and 42 GIPs occurred in the groups that received a JAKi and adalimumab groups; incidence rates were 2.1 (95% confidence interval [CI] 1.5–2.8) and 1.1 (95% CI 0.8–1.5) per 1,000 person‐years, respectively. Rates of GIP did not differ between the groups that received a JAKi and adalimumab: wHR 1.1 (95% CI 0.7–1.9; P = 0.65). Despite the lack of power in some subgroup analyses, results were consistent whatever the subgroup of a type of JAKi received or subgroup with a type of rheumatic disease. Conclusion: In this nationwide cohort study, the rates of GIPs did not differ between groups of patients who received JAKi and adalimumab treatment. These results need to be confirmed in other observational studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Angiographic results of surgical or endovascular treatment of intracranial aneurysms: a systematic review and inter-observer reliability study

Author

Benomar, Anass, Farzin, Behzad, Volders, David, Gevry, Guylaine, Zehr, Justine, Fahed, Robert, Boisseau, William, Gentric, Jean-Christophe, Magro, Elsa, Nico, Lorena, Roy, Daniel, Weill, Alain, Mounayer, Charbel, Guilbert, François, Létourneau-Guillon, Laurent, Jacquin, Gregory, Chaalala, Chiraz, Kotowski, Marc, Nguyen, Thanh N., Kallmes, David, White, Phil, Darsaut, Tim E., and Raymond, Jean

Published
2021
Full Text
View/download PDF

29. Surgical or Endovascular Management of Middle Cerebral Artery Aneurysms: A Randomized Comparison

Author

Darsaut, Tim E., Keough, Michael B., Sagga, Abdelaziz, Chan, Vivien K.Y., Diouf, Ange, Boisseau, William, Magro, Elsa, Kotowski, Marc, Roy, Daniel, Weill, Alain, Iancu, Daniela, Bojanowski, Michel W., Chaalala, Chiraz, Bilocq, Alain, Estrade, Laurent, Lejeune, Jean-Paul, Bricout, Nicolas, Scholtes, Felix, Martin, Didier, Otto, Bernard, Findlay, J. Max, Chow, Michael M., O’Kelly, Cian J., Ashforth, Robert A., Rempel, Jeremy L., Lesiuk, Howard, Sinclair, John, Altschul, David J., Arikan, Fuat, Guilbert, Francois, Chagnon, Miguel, Farzin, Behzad, Gevry, Guylaine, and Raymond, Jean

Published
2021
Full Text
View/download PDF

31. Comprehensive Aneurysm Management (CAM): An All-Inclusive Care Trial for Unruptured Intracranial Aneurysms

Author

Darsaut, Tim E., Desal, Hubert, Cognard, Christophe, Januel, Anne-Christine, Bourcier, Romain, Boulouis, Grégoire, Shiva Shankar, Jai Jai, Findlay, J. Max, Rempel, Jeremy L., Fahed, Robert, Boccardi, Edoardo, Valvassori, Luca, Magro, Elsa, Gentric, Jean-Christophe, Bojanowski, Michel W., Chaalala, Chiraz, Iancu, Daniela, Roy, Daniel, Weill, Alain, Diouf, Ange, Gevry, Guylaine, Chagnon, Miguel, and Raymond, Jean

Published
2020
Full Text
View/download PDF

37. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines

Author

Le Vu, Stéphane, primary, Bertrand, Marion, additional, Botton, Jérémie, additional, Jabagi, Marie-Joelle, additional, Drouin, Jérôme, additional, Semenzato, Laura, additional, Weill, Alain, additional, Dray-Spira, Rosemary, additional, and Zureik, Mahmoud, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results